Halazepam

Halazepam

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a684001
Pregnancy category	?
Routes of administration	Oral
ATC code	N05BA13 (WHO)
Legal status
Legal status	CA: Schedule IV DE: Anlage III (Prescription only) US: Schedule IV
Pharmacokinetic data
Metabolism	Hepatic
Biological half-life	14 hours (halazepam), 50–100 hours (metabolites).
Excretion	Renal
Identifiers
IUPAC name 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one
Synonyms	9-chloro-6-phenyl-2-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one
CAS Number	23092-17-3 Y
PubChem CID	31640
IUPHAR/BPS	7195
DrugBank	DB00801 Y
ChemSpider	29343 Y
UNII	320YC168LF
KEGG	D00338 Y
ChEMBL	CHEMBL970 Y
ECHA InfoCard	100.041.281
Chemical and physical data
Formula	C17H12ClF3N2O
Molar mass	352.7 g/mol
3D model (Jmol)	Interactive image
SMILES FC(F)(CN1C(CN=C(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3)=O)F
InChI InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2 Y Key:WYCLKVQLVUQKNZ-UHFFFAOYSA-N Y

Halazepam is a benzodiazepine derivative that was marketed under the brand names Paxipam in the United States,Alapryl in Spain, and Pacinone in Portugal.

Halazepam was used for the treatment of anxiety.

Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.

Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published in June 15, 1998 as follows:

Halazepam is classified as a schedule 4 controlled substance with a corresponding code 2762 by the Drug Enforcement Administration (DEA).

Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.